Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

The United States has reported 53 new measles cases, bringing the 2026 total to 2,371, according to the latest data from the Centers for Disease Control and Prevention (CDC).

Amid the rising outbreak, US Health Secretary Robert F. Kennedy Jr. urged American parents to vaccinate their children against the highly contagious disease.

The CDC said that of the 53 new cases, 16 were locally acquired across 45 US jurisdictions, while the remaining cases were linked to international travel.

Highest Measles Toll In 35 Years

Although measles is preventable through vaccination, the 2,371 cases reported as of July 30 have already surpassed the 2,289 cases recorded during all of 2025. Both years represent the highest annual measles totals in the US since 1991.

The US was declared measles-free in 2000, but it could lose that status later this year when the Pan American Health Organization reviews transmission data.

Measles by the numbers:

• 2,371 measles cases reported in 2026.
• 20% of cases are in children under 5; 49% are in those 5–19 years.
• 7% of patients have been hospitalized, compared with 11% in 2025.
• No deaths have been reported.
• 93% of cases are in people who are unvaccinated or have unknown vaccination status.

Current measles hotspots:

• Pennsylvania: 31 new cases in the past week; 167 total cases in 2026.
• Ohio: Four new cases in unvaccinated individuals in Ashtabula and Tuscarawas counties; the state's third measles outbreak of 2026.
• Utah: Largest active outbreak with 514 cases; no new cases reported this week.
• Arizona: One new case; 120 total cases in 2026.
• Washington: Seven new cases; 53 total cases in 2026.

Kennedy Urges Parents to Vaccinate Children

In a notable shift, Kennedy urged American parents to vaccinate their children against measles during a CNN interview.

Long known as a vaccine skeptic, Kennedy has spent years amplifying misinformation about vaccines, including the measles, mumps and rubella (MMR) vaccine. His remarks came as US measles cases surpassed the 2025 annual total.

The past two years have seen more measles infections in the US than the rest of the 21st century combined. More than 90% of cases have occurred in people who are unvaccinated or whose vaccination status is unknown.

"I've never questioned the efficacy of the MMR vaccine," the Healthy Secretary said.

Kennedy also blamed low vaccination rates in some religious communities for ongoing outbreaks.

"The communities that are suffering from measles are almost all religious communities that just don't vaccinate," Kennedy told CNN.

Kennedy Repeats Debunked Vaccine Claims

During the interview, Kennedy also blamed pandemic lockdowns on Dr. Anthony Fauci while repeating several widely debunked claims about vaccines and other health issues.

He claimed that respiratory syncytial virus (RSV) is a major cause of infant mortality, suggested Lyme disease was caused by laboratory manipulation of germs, repeated unsupported claims linking Tylenol use during pregnancy to autism, and questioned the effectiveness of COVID-19 vaccines for children.

Large studies conducted over several decades in multiple countries have consistently found no evidence that routine childhood vaccines cause autism.

Major medical associations also continue to consider acetaminophen the preferred pain reliever and fever reducer during pregnancy when used appropriately. They have also cautioned against avoiding acetaminophen altogether, noting that untreated high fever or severe pain during pregnancy can pose risks to both the mother and the developing baby.

Speaking to CNN, Ashish Jha, former White House COVID-19 response coordinator under President Joe Biden, said the rise in measles cases was not coincidental.

"The administration has not done enough to promote vaccines. It has not done enough to highlight the harms that come from measles."

Jha added that "accountability has to be with our political leaders," while criticizing Kennedy's false claims about vaccines.

A 58-year-old woman in the UK has become the first person in the world to receive an experimental cell therapy for ovarian cancer.

Tracy Tomlinson, who has been living with advanced ovarian cancer for more than five years, received the first dose of ZI-MA4-1 at The Christie NHS Foundation Trust as part of the ZIMA-101 clinical trial. The study is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development.

"While this is an early-stage study primarily focused on safety, it represents an exciting step forward in efforts to develop new treatment options for people like Tracy with advanced solid tumors. We hope the knowledge gained will help shape future cancer treatments and ultimately improve outcomes for patients," said Professor Fiona Thistlethwaite, consultant medical oncologist at The Christie.

Tracy's Journey With Ovarian Cancer

Tracy, from Chadderton in Greater Manchester, was diagnosed with Stage 3C ovarian cancer shortly before Christmas 2020.

She first suspected something was wrong when what she thought was a urinary tract infection did not improve despite antibiotics prescribed by her GP. After blood tests, scans and further investigations, she was diagnosed with ovarian cancer just two days before her birthday.

Over the next several years, Tracy underwent surgery, multiple rounds of chemotherapy and maintenance therapy. By the summer of 2021, scans showed no evidence of disease, but the cancer returned a year later. She underwent further surgery and treatment, followed by additional recurrences.

Since 2023, Tracy has been living with ongoing cancer while receiving additional lines of treatment.

"The cancer is relentless," she said. "For me, it's never seemed to leave me alone."

Treatment has also caused fatigue, nausea and nerve damage in her hands and feet, eventually forcing her to stop working as a credit controller.

As her treatment options became more limited, Tracy began exploring clinical trials. Last year, she was referred to The Christie's early-phase clinical trials team and was eventually found eligible for the ZIMA-101 study.

After extensive screening, including scans, biopsies and blood tests, she became the first patient in the world to receive ZI-MA4-1.

"I decided almost straight away that I was going to go for it," she said. "Then afterwards you think, 'Am I doing the right thing?' because it is a little bit scary being the first person."

Following her first dose, Tracy remained in hospital for planned monitoring before being discharged on July 23.

"There are no guarantees with any trial," she said. "It could have a fantastic outcome, it could have no outcome, or somewhere in between. But if there is a possibility that it could work, I've got to go for it."

She added, "Cancer is no longer a death sentence. Five years ago, I thought I was going to die, but I'm still here."

What Is ZI-MA4-1 Cell Therapy?

Developed by Zelluna, ZI-MA4-1 combines two immune-based approaches to target cancer. The therapy uses natural killer (NK) cells, which can detect and destroy abnormal cells, together with engineered T-cell receptors (TCRs) that enable them to recognize tumors expressing the protein MAGE-A4.

MAGE-A4 is found in several solid tumors, including ovarian cancer, making it a promising target for precision cancer therapies.

Unlike personalized cell therapies that require a patient's own cells to be collected and manufactured individually, ZI-MA4-1 uses donor-derived immune cells and is designed as an "off-the-shelf" treatment.

Researchers hope this approach could make advanced cell therapies available to more patients in less time.

Reducing sugar intake during pregnancy and the first two years of a child’s life could have life-changing benefits for brain health, particularly in lowering the risk of Alzheimer’s disease.

According to a new study, limiting sugar intake could reduce the risk Alzheimer’s by more than 45% in the future.

The research, published in npj Aging, found that people exposed to lower sugar intake during the first 1,000 days of life, from conception until age two, had a 46% lower risk of Alzheimer’s disease, a 27% lower risk of dementia, an 11% lower risk of depression, and a 20% lower risk of anxiety in later life.

Researchers analysed health and brain imaging data from more than 60,000 participants in the UK Biobank.

They used Britain’s World War II sugar rationing period as a natural experiment, comparing people born when sugar availability was restricted with those born after rationing ended.

Why The First 1,000 Days Matter?

Scientists say that early life is a critical phase for the brain, metabolism, and immune system. Nutrition during this period can shape long-term health, influencing disease risk of neurodegenerative disease decades later.

“Our findings suggest that limiting sugar intake during the first 1,000 days of life may have long-lasting benefits for brain health,” the researchers noted, adding that the effects appear to persist well into older adulthood.

Dr. Bing Zhang, a geriatric medicine researcher involved in the study, said the results support the idea that nutrition in early life can shape lifelong brain health through metabolic programming during critical stages of development.

The study also found key structural differences in the brain. MRI scans showed that participants who had lower sugar exposure early in life had brains that appeared approximately 0.4 years younger biologically.

Their brains showed greater grey matter volume and fewer signs of white matter damage that is often linked to healthier cognitive ageing.

Also read: Can Your Child’s Diet Shape Future Diabetes Risk? Study Links Ultra-Processed Foods To Early Insulin Responses

Does Sugar Cause Dementia?

The researchers found an association, not proof that sugar directly causes Alzheimer’s or dementia. Since the study is observational, other factors like overall diet, access to healthcare facilities and services, and lifestyle may also have contributed to the findings.

Dr. Sara Rodrigues of Alzheimer’s Research UK, who was not involved in the research, cautioned that while the results are compelling, they do not establish cause and effect. However, they add to the growing evidence that healthy eating throughout life plays an important role in maintaining brain health.

Ultra-Processed Foods Linked To Early Insulin Response

This comes after a recent study suggested that children who who consume higher amounts of ultra-processed foods may already be showing subtle changes in the way their bodies regulate insulin, potentially increasing the risk for type 2 diabetes in the future.

According to a new study published in the journal Nutrients, children who have higher amounts of in ultra-processed foods (UPFs) had reduced insulin sensitivity and higher insulin secretion, even though they did not have diabetes.

Researchers from Texas A&M University–San Antonio, University of Texas Health San Antonio, University of Texas Rio Grande Valley, and Wake Forest University School of Medicine discovered that the metabolic changes linked to diabetes may begin much earlier in life than previously thought.